Obtained ISO 14001: 2015 Environmental Management System Certificate.

Passed the intellectual property management system certification.

Received the C-round financing.

"Tacarbitol" project obtained the certificate of Shanghai high-tech achievement transformation project.

Chemexpress entrepreneurial team won the third prize of Shanghai Pudong Science and Technology Award.

Became an enterprise R&D institution in Pudong New Area, Shanghai, and a Shanghai brand cultivation demonstration enterprise.

Anhui Haoyuan Pharmaceutical Co., Ltd. was under construction.

"Alcalcidol and its intermediates" project won the certificate of high-tech achievement transformation project and the third prize of Shanghai Pudong New Area Science and Technology Award.

Established and improved the pharmaceutical solid-state chemistry research technology platform.

Won the honorary title of "Shanghai Famous Brand Enterprise (Star of Tomorrow)".

Appraised as "2017 Patent Work Pilot Unit Recognition".

Established in "Key Scientific and Technological Venture Enterprise Special Funds of 2017 Pudong Science and Technology Development Fund ".

After a decade of grinding sword, Shanghai Haoyuan Chemexpress Co., Ltd. was successfully listed on the National Equities Exchange and Quotations, with the stock code of 837278.

Obtained the B-round financing.

Recognized as a Shanghai Science and Technology Small Giant Cultivation Enterprise.

The " research and development of MMAE series of antibody-coupled drug" project was successfully approved for the 2016 Shanghai Innovation Fund.

Established and improved the development platform of HPAPI.

The system of Shanghai HaoyuanChemexpress Co., Ltd. changed to the limited company system.

The " research and development of a new drug for hepatitis C treatment of sofosbuvir and its tablets" was successfully approved for the Shanghai "Science and Technology Innovation Action Plan" for the cooperation project of industry-university-research-medicine in the biomedical field.

The "industrialization of carfilzomib and its advanced intermediates and research and development of new anti-tumor drugs" project was successfully approved for the Shanghai "Science and Technology Innovation Action Plan" technology innovation fund project for technology-based small and medium-sized enterprises.

Received the A-round financing.

The "Teliliptin and its key intermediates research and development" project was successfully approved for the 2014 Shanghai Innovation Fund.

The characteristic vitamin D series product "Research and Development of Paricalcitol and Its Intermediates" was successfully approved for the 2013 Shanghai Innovation Fund.

Obtained the ISO 9001:2008 quality system certification.

Won the honorary title of "Hi-Tech Enterprise".

The "Innovative Research and Development of Asenapine Synthetic Process" project was successfully approved for the 2011 Shanghai Innovation Fund.

Shanghai Haoyuan Medchemexpress Co., Ltd., a wholly-owned subsidiary, was registered and established in Zhangjiang Hi-Tech Park, which laid the foundation for the establishment and growth of the small molecule chemical compound library.

Chemexpress "chiral all-synthetic natural product Triptolide and novel anti-tumor activity Triptolide derivative" project was successfully submitted in 2009. for Shanghai Innovation Fund.

Established and improved high-end API and intermediate R&D technical services.

Settled in Zhangjiang China Pharmaceutical Valley Biomedical Base.

Chemexpress undertook the National 863 Program "discovery of new anti-Mycobacterium tuberculosis precursor compound and its function evaluation" jointly with Fudan University and Huazhong University of Science and Technology.

Shanghai Haoyuan Chemexpress Co., Ltd. Was founded in 2006 by Dr Zheng Baofu, Dr Gao Qiang and Dr Xue Jijun in Shanghai.